Log in

Acceleron Pharma Stock Forecast, Price & News

+2.33 (+2.24 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $106.56
50-Day Range
MA: $96.24
52-Week Range
Now: $106.56
Volume711,303 shs
Average Volume645,478 shs
Market Capitalization$6.38 billion
P/E RatioN/A
Dividend YieldN/A
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Read More
Acceleron Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.89 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:XLRN



Sales & Book Value

Annual Sales$73.99 million
Book Value$8.47 per share


Net Income$-124,860,000.00
Net Margins-157.84%


Market Cap$6.38 billion
Next Earnings Date11/4/2020 (Estimated)
+2.33 (+2.24 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

How has Acceleron Pharma's stock been impacted by COVID-19 (Coronavirus)?

Acceleron Pharma's stock was trading at $84.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XLRN stock has increased by 26.3% and is now trading at $106.56.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Acceleron Pharma?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 1 sell rating, 1 hold rating, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Acceleron Pharma

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Acceleron Pharma

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc (NASDAQ:XLRN) posted its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.55) by $0.21. The biopharmaceutical company had revenue of $39.75 million for the quarter, compared to the consensus estimate of $30.08 million. Acceleron Pharma had a negative return on equity of 31.62% and a negative net margin of 157.84%. The company's revenue for the quarter was up 43.7% on a year-over-year basis. During the same period last year, the company earned ($0.34) EPS.
View Acceleron Pharma's earnings history

What price target have analysts set for XLRN?

14 brokers have issued 12-month price targets for Acceleron Pharma's shares. Their forecasts range from $71.00 to $155.00. On average, they anticipate Acceleron Pharma's share price to reach $120.57 in the next year. This suggests a possible upside of 13.1% from the stock's current price.
View analysts' price targets for Acceleron Pharma

Are investors shorting Acceleron Pharma?

Acceleron Pharma saw a increase in short interest in August. As of August 14th, there was short interest totaling 3,380,000 shares, an increase of 8.3% from the July 30th total of 3,120,000 shares. Based on an average daily trading volume, of 737,000 shares, the short-interest ratio is presently 4.6 days. Approximately 6.6% of the company's shares are short sold.
View Acceleron Pharma's Short Interest

Who are some of Acceleron Pharma's key competitors?

What other stocks do shareholders of Acceleron Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Intel (INTC), Corcept Therapeutics (CORT), Cisco Systems (CSCO), Pfizer (PFE) and Square (SQ).

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the following people:
  • Mr. Habib J. Dable, CEO, Pres & Director (Age 50)
  • Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 76)
  • Mr. Kevin F. McLaughlin, Sr. VP, CFO & Treasurer (Age 63)
  • Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 59)
  • Dr. John D. Quisel, Exec. VP, Chief Bus. Officer & Sec. (Age 48)

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Who are Acceleron Pharma's major shareholders?

Acceleron Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (12.81%), Vanguard Group Inc. (7.24%), Artal Group S.A. (2.34%), TimesSquare Capital Management LLC (1.81%), Cormorant Asset Management LP (1.00%) and Goldman Sachs Group Inc. (0.82%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Ravindra Kumar, Sujay Kango and Thomas A Mccourt.
View institutional ownership trends for Acceleron Pharma

Which major investors are selling Acceleron Pharma stock?

XLRN stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, FMR LLC, Nuveen Asset Management LLC, Cormorant Asset Management LP, Orbimed Advisors LLC, Candriam Luxembourg S.C.A., Artal Group S.A., and State of Wisconsin Investment Board. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Corp /De/ Celgene, Habib J Dable, John D Quisel, Kevin F Mclaughlin, Sujay Kango, and Thomas A Mccourt.
View insider buying and selling activity for Acceleron Pharma

Which major investors are buying Acceleron Pharma stock?

XLRN stock was acquired by a variety of institutional investors in the last quarter, including Bamco Inc. NY, Man Group plc, Marshall Wace North America L.P., New York State Common Retirement Fund, Holocene Advisors LP, Rhenman & Partners Asset Management AB, Deerfield Management Company L.P. Series C, and Two Sigma Advisers LP. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene, and Joseph S Zakrzewski.
View insider buying and selling activity for Acceleron Pharma

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $106.56.

How big of a company is Acceleron Pharma?

Acceleron Pharma has a market capitalization of $6.38 billion and generates $73.99 million in revenue each year. The biopharmaceutical company earns $-124,860,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.

What is Acceleron Pharma's official website?

The official website for Acceleron Pharma is www.acceleronpharma.com.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.